share_log

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 18.6% in April

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 18.6% in April

Armata Pharmicals, Inc.(纽约证券交易所美国证券交易所代码:ARMP)4月份空头利率上涨了18.6%
Financial News Live ·  2023/05/02 02:43

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 32,500 shares, an increase of 18.6% from the March 31st total of 27,400 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 15,400 shares, the short-interest ratio is currently 2.1 days.

Armata制药公司(纽约证券交易所代码:ARMP-GET Rating)是4月份空头股数大幅增长的接受者。截至4月15日,空头股数共有3.25万股,比3月31日的2.74万股增加了18.6%。目前,该公司0.3%的股份被卖空。以日均成交量15,400股计算,目前短息比为2.1天。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Friday, March 17th.

另外,HC Wainwright在3月17日(星期五)的一份报告中重申了“买入”评级,并对Armata制药公司的股票发布了7.00美元的目标价。

Get
到达
Armata Pharmaceuticals
Armata制药公司
alerts:
警报:

Institutional Inflows and Outflows

机构资金流入和流出

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. HRT Financial LP purchased a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $52,000. Jane Street Group LLC purchased a new position in shares of Armata Pharmaceuticals during the fourth quarter valued at approximately $25,000. Northern Trust Corp purchased a new position in shares of Armata Pharmaceuticals during the first quarter valued at approximately $95,000. Vanguard Group Inc. boosted its position in shares of Armata Pharmaceuticals by 5.2% during the third quarter. Vanguard Group Inc. now owns 287,350 shares of the company's stock valued at $1,213,000 after buying an additional 14,200 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Armata Pharmaceuticals by 5.6% during the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock valued at $91,000 after buying an additional 3,900 shares during the period. Hedge funds and other institutional investors own 3.76% of the company's stock.

机构投资者和对冲基金最近增持或减持了该股。HRT Financial LP在第四季度购买了Armata制药公司新的股票头寸,价值约5.2万美元。简街集团在第四季度购买了Armata制药公司新的股票头寸,价值约2.5万美元。北方信托公司在第一季度购买了Armata制药公司的新头寸,价值约9.5万美元。先锋集团(Vanguard Group Inc.)在第三季度将其在Armata PharmPharmticals的股票头寸增加了5.2%。先锋集团目前持有287,350股该公司股票,价值1,213,000美元,在此期间又购买了14,200股。最后,复兴科技有限责任公司在第四季度将其在Armata制药公司的股票头寸提高了5.6%。复兴科技有限责任公司现在拥有73,696股该公司的股票,价值91,000美元,在此期间又购买了3,900股。对冲基金和其他机构投资者持有该公司3.76%的股份。

Armata Pharmaceuticals Stock Down 0.1 %

Armata制药类股下跌0.1%

Shares of Armata Pharmaceuticals stock traded down $0.00 during trading on Monday, reaching $1.62. 728 shares of the stock traded hands, compared to its average volume of 15,264. The firm has a market cap of $58.52 million, a price-to-earnings ratio of -1.43 and a beta of 1.17. Armata Pharmaceuticals has a 52-week low of $0.83 and a 52-week high of $4.92.

在周一的交易中,Armata PharmPharmticals的股价下跌了0.00美元,达到1.62美元。该股有728股易手,而其平均成交量为15,264股。该公司的市值为5852万美元,市盈率为-1.43倍,贝塔系数为1.17。Armata PharmPharmticals的52周低点为0.83美元,52周高点为4.92美元。

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last issued its quarterly earnings data on Thursday, March 16th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). The firm had revenue of $1.05 million for the quarter, compared to analysts' expectations of $1.34 million. Armata Pharmaceuticals had a negative net margin of 670.26% and a negative return on equity of 75.16%. On average, equities analysts expect that Armata Pharmaceuticals will post -1.31 EPS for the current fiscal year.

Armata制药公司(NYSEAMERICAN:ARMP-GET Rating)最近一次发布季度收益数据是在3月16日星期四。该公司公布本季度每股收益为0.29美元,低于分析师普遍预期的0.25美元和0.04美元。该公司当季营收为105万美元,高于分析师预期的134万美元。阿玛塔制药公司的净利润率为负670.26%,净资产回报率为负75.16%。股票分析师平均预计,Armata PharmPharmticals本财年的每股收益将为1.31美元。

Armata Pharmaceuticals Company Profile

Armata制药公司简介

(Get Rating)

(获取评级)

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Armata制药公司是一家临床阶段的生物技术公司,专注于开发用于治疗抗药性细菌感染的噬菌体疗法。该公司成立于2019年5月9日,总部位于加利福尼亚州洛杉矶。

Read More

阅读更多内容

  • Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
  • Insiders Drive Volatility For Keurig Dr Pepper
  • After a 40% Drop, Analysts Remain Bullish on Impinj
  • Visa Charges Higher After Better-Than-Expected Q2 Report
  • onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
  • Can Teladoc Stock Be Resuscitated?
  • 免费获取StockNews.com关于Armata制药的研究报告(ARMP)
  • 内部人士推动Keurig Dr Pepper的波动
  • 在下跌40%之后,分析师仍看好Impinj
  • 第二季度报告好于预期后签证费用上涨
  • On Semi芯片类股触底,创新高
  • Teladoc股票可以复苏吗?

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

获得Armata制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Armata制药和相关公司的最新新闻和分析师评级的每日简要摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发